^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CD19 underexpression

i
Other names: CD19, CD19 Molecule, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, Differentiation Antigen CD19, B-Lymphocyte Antigen CD19, CD19 Antigen, CVID3, B4
Entrez ID:
Related biomarkers:
8ms
Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency. (PubMed, J Clin Invest)
CD19low resistant cells exhibited preserved B cell receptor signaling and were more sensitive to both BTK and MEK inhibition. These data demonstrate that resistance to CD19 immunotherapies can result in decreased expression of both CD19 and CD22 and can result in dependency on BTK pathways.
Journal • IO biomarker
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD19 expression • CD22 expression • CD19 underexpression
10ms
Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma. (PubMed, Nat Med)
The phase 3 ZUMA-7 trial in second-line large B cell lymphoma demonstrated superiority of anti-CD19 CAR T cell therapy (axicabtagene ciloleucel (axi-cel)) over standard of care (SOC; salvage chemotherapy followed by hematopoietic transplantation) ( NCT03391466 ). T cell activation and B cell GES, which are associated with improved axi-cel outcome, decreased with increasing lines of therapy. These data highlight differences in resistance mechanisms to axi-cel and SOC and support earlier intervention with axi-cel.
Journal • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
CD19 expression • CD19 underexpression
|
Yescarta (axicabtagene ciloleucel) • HD-CAR-1
1year
Blocking the CD47-SIRPα Axis enhances Tafasitamab-mediated phagocytosis (DGHO 2023)
In addition, the inhibitory receptor of CD47, signal regulatory protein alpha (SIRPα) is increased on macrophages from patients with follicular lymphoma who relapse or progress after frontline lenalidomide and rituximab. We show that CD47 and SIRPα were elevated in lymph node biopsies from DLBCL patients. Increased expression of SIRPα on macrophages correlated with decreased ADCP activity of tafasitamab, and CRISPR-mediated CD47 overexpression on lymphoma targets impaired tafasitamab-mediated phagocytosis, in vitro. Combination of tafasitamab and an anti-CD47 enhanced ADCP activity of in vitro generated macrophages.
IO biomarker
|
CD19 (CD19 Molecule) • CD47 (CD47 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
|
CD19 expression • CD47 overexpression • CD19 underexpression • CD47 expression
|
Rituxan (rituximab) • lenalidomide • Monjuvi (tafasitamab-cxix)
1year
CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression. (PubMed, J Immunother Cancer)
CLN-978 warrants further exploration. An ongoing clinical phase 1 trial is investigating safety, pharmacokinetics, pharmacodynamics, and the initial therapeutic potential of subcutaneously administered CLN-978 in patients with non-Hodgkin's lymphoma.
Journal
|
CD19 (CD19 Molecule)
|
CD19 expression • CD19 underexpression
|
CLN-978
almost2years
Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis (ASH 2022)
In addition, the inhibitory receptor of CD47, signal regulatory protein alpha (SIRPα) is increased on macrophages from patients with follicular lymphoma who relapse or progress after frontline lenalidomide and rituximab (Marques-Piubelli et al). Conclusion Our results show increased expression of CD47-SIRPa axis in primary DLBCL samples and indicate that CD47 blockade can enhance the phagocytic potential of tumor-targeting immunotherapies such as tafasitamab. Our findings suggest that there is merit in exploring the clinical utility of combining tafasitamab with an anti-CD47 blocking antibody in lymphoma.
IO biomarker
|
CD47 (CD47 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
|
CD19 expression • CD47 overexpression • CD19 underexpression • CD47 expression
|
Rituxan (rituximab) • lenalidomide • Monjuvi (tafasitamab-cxix)